查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678678

胜肽治療市場規模、佔有率、趨勢分析報告：按應用、類型、製造商類型、給藥途徑、合成技術、地區、細分預測，2025-2030 年

Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturer, By Route Of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

肽治療市場的成長和趨勢

根據Grand View Research, Inc.的一份新報告，到2030年全球胜肽治療市場規模預計將達到2,602.5億美元。

預計 2025 年至 2030 年的複合年成長率為 10.77%。對治療癌症和其他文明病的有效、快速且副作用較少的治療方法的需求不斷成長，預計將推動市場成長。癌症發生率的上升促使人們探索和採用替代治療方式和低成本治療方案，預計這將推動市場的發展。此外，老年人口的增加預計將引發癌症和糖尿病等目標疾病的流行，從而擴大消費群，從而推動對肽療法的需求。

根據國際癌症研究機構（GLOBOCAN 2020）的報告，2020年全球將有19,292,789例新診斷癌症病例，癌症死亡人數將達到9,958,133人。此外，預計全球5年癌症盛行率將達50,550,287例。到 2040 年，全球新增癌症病例數預計將達到 28,887,940 例。因此，預計預測期內全球癌症發生率的上升將在肽療法的發展中發揮關鍵作用。此外，醫療保健提供者和患者對化療和放射線治療的副作用的認知不斷提高，這是影響對肽類藥物等替代療法日益重視的主要因素。

在預測期內，胜肽製造流程的技術進步正在推動市場的發展。製造商和供應商正致力於採用新技術，以更少的時間和資本投入有效地生產藥物分子。改進的精製和自動化流程以及減少的廢棄物產生是促進市場成長的進一步因素。例如，安進公司於2022年3月宣布將在北卡羅來納州霍利斯普林斯正式開設其最新的生物製造工廠。該工廠計劃於 2025 年投入營運，將有助於滿足安進公司治療癌症和心臟病等嚴重疾病的藥物的成長需求。

根據2020年《自然·癌症》雜誌發表的一篇研究論文，COVID-19大流行預計將加速癌症治療的頻譜變化，包括延遲診斷和治療性介入，以及阻礙專注於開發具有成本效益的癌症治療頻譜的臨床試驗，而用於癌症治療的肽療法也不例外。截至2020年5月，用於治療COVID-19的胜肽藥物共有21種，其中包括15種用於治療急性呼吸窘迫症候群（ARDS）和嚴重急性呼吸道感染疾病引起的其他呼吸系統疾病的合成胜肽。然而，目前肽療法在癌症、代謝疾病和其他疾病中的實用化受到藥物短缺、操作問題和臨床試驗進展緩慢的阻礙，包括用於治療除 COVID-19 以外的疾病。

例如，2022 年 5 月，EVER Pharma 宣布硼Bortezomib獲得歐盟範圍內核准，用於治療症狀性骨髓瘤和套細胞淋巴瘤。 1 2022 年 5 月，歐盟委員會核准諾華的 Jakavi 類固醇後療法，用於治療急性和慢性移植物抗宿主疾病。 Jakavi 將成為歐洲首個可廣泛用於治療類固醇抗性移植物抗宿主疾病患者的 JAK1/2 抑制劑。 2021 年 9 月，Nimble Therapeutics 與 Incyte 達成策略合作，以發現更多新型胜肽療法。

肽治療市場報告重點

  • 按類型分類，學名藥是市場上第二大藥物。學名藥的興起是製藥業的新興趨勢。
  • 由於對需要複雜程序並有助於降低製造成本的外包的偏好發生變化，預計外包製造部門在預測期內將以最快的複合年成長率成長。
  • 以合成技術計算，重組 DNA 技術部門在 2024 年佔據最大的收益佔有率，為 79.26%。
  • 受癌症、代謝疾病和罕見疾病盛行率上升的推動，北美胜肽治療市場預計將在 2024 年保持主導，佔據全球 60.21% 的佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 胜肽治療市場變數、趨勢和範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肽治療分析工具
    • 波特的分析
    • PESTEL 分析
  • 管道分析
    • 第 1 階段
    • 第 2 階段
    • 第 3 階段
  • 3 期藥物研發預測
  • 使用案例分析

第 4 章胜肽治療市場：按應用進行的估計和趨勢分析

  • 胜肽治療市場：應用細分儀表板
  • 胜肽治療市場：應用趨勢分析，2024 年和 2030 年
  • 代謝紊亂
  • 癌症
  • 神經系統疾病
  • 胃腸道疾病
  • 心血管疾病
  • 疼痛
  • 感染疾病
  • 腎臟疾病
  • 皮膚病
  • 呼吸系統疾病
  • 其他

第 5 章胜肽治療市場：按類型估計和趨勢分析

  • 胜肽治療市場：類型細分儀表板
  • 胜肽治療市場：類型變化分析，2024 年與 2030 年
  • 創新的
  • 非專利的

第 6 章胜肽治療市場：按製造商類型進行的估計和趨勢分析

  • 胜肽治療市場：製造商類型細分儀表板
  • 胜肽治療市場：製造商類型變化分析，2024 年與 2030 年
  • 內部
  • 外包

第 7 章胜肽治療市場：合成技術的估計與趨勢分析

  • 胜肽治療市場：合成技術細分儀表板
  • 胜肽治療市場：合成技術變化分析，2024 年與 2030 年
  • 重組DNA技術
  • 固相胜肽合成（SPPS）
  • 混合
  • 液相肽合成（LPPS）
  • 其他

第 8 章胜肽治療市場：按給藥途徑的估計和趨勢分析

  • 胜肽治療市場：給藥途徑細分儀表板
  • 胜肽治療市場：給藥途徑變異分析，2024 年和 2030 年
  • 腸外給藥
  • 口服
  • 黏膜
  • 肺
  • 其他

第9章肽治療市場：區域、估計和趨勢分析

  • 肽類治療市場佔有率（按地區分類），2024 年和 2030 年，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 主要市場參與企業的近期趨勢及影響分析
  • 公司分類
  • 參與者概述
  • Product Bench Marking
  • 2024 年公司市場佔有率分析
  • 公司簡介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Novo Nordisk A/S
    • GSK plc
    • Ironwood Pharmaceuticals, Inc.
    • Radius Health, Inc.（Gurnet Point Capital 和 Patient Square Capital 的子公司）
    • Ipsen Pharma

第 11 章結論/關鍵要點/KoL 見解

Product Code: 978-1-68038-179-5

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 260.25 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 10.77% from 2025 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

  • By type, the generic segment is the second largest segment in the market. The rise of generic peptide therapeutics is an emerging trend in the pharmaceutical industry
  • Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
  • Based on synthesis technology, the recombinant DNA technology segment accounted for the largest revenue share of 79.26% in 2024
  • The North America Peptide Therapeutics market maintains a leading position in 2024 with share of 60.21% globally in 2024, driven by the rising prevalence of cancer, metabolic disorders, and rare diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of cancer
        • 3.3.1.1.1. Cancer incidence data
      • 3.3.1.2. Technological advancements
      • 3.3.1.3. Presence of strong product pipeline
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Increasing complexity of peptides
      • 3.3.2.2. High cost of manufacturing equipment
  • 3.4. Peptide Therapeutics Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3
  • 3.6. Phase 3 Pipeline Drug Forecasts
  • 3.7. Case Studies Analysis

Chapter 4. Peptide Therapeutics Market: By Application Estimates & Trend Analysis

  • 4.1. Peptide Therapeutics Market: Application Segment Dashboard
  • 4.2. Peptide Therapeutics Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Metabolic Disorders
    • 4.3.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Cancer
    • 4.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Neurological Disorders
    • 4.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Gastrointestinal Disorders
    • 4.6.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Cardiovascular Disorders
    • 4.7.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Pain
    • 4.8.1. Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Infectious Disease
    • 4.9.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Renal Disorders
    • 4.10.1. Renal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.11. Dermatological Disorders
    • 4.11.1. Dermatological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.12. Respiratory Disorders
    • 4.12.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.13. Others
    • 4.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Therapeutics Market: Type Estimates & Trend Analysis

  • 5.1. Peptide Therapeutics Market: Type Segment Dashboard
  • 5.2. Peptide Therapeutics Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Innovative
    • 5.3.1. Innovative Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Generic
    • 5.4.1. Generic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis

  • 6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
  • 6.2. Peptide Therapeutics Market: By Type of Manufacturer Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Inhouse
    • 6.3.1. Inhouse Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Outsourced
    • 6.4.1. Outsourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis

  • 7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
  • 7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Recombinant DNA Technology
    • 7.3.1. Recombinant DNA Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Solid-Phase Peptide Synthesis (SPPS)
    • 7.4.1. Solid-Phase Peptide Synthesis (SPPS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Hybrid
    • 7.5.1. Hybrid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Liquid-Phase Peptide Synthesis (LPPS)
    • 7.6.1. Liquid-Phase Peptide Synthesis (LPPS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
  • 8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 8.3. Parenteral Route
    • 8.3.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Oral Route
    • 8.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Mucosal
    • 8.5.1. Mucosal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Pulmonary
    • 8.6.1. Pulmonary Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Peptide Therapeutics Market Share, By Region, 2024 & 2030, USD Million
  • 9.2. North America
    • 9.2.1. North America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Target Disease Prevalence
      • 9.2.2.3. Regulatory Framework
      • 9.2.2.4. Reimbursement Framework
      • 9.2.2.5. U.S. Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Regulatory Framework
      • 9.2.3.4. Reimbursement Framework
      • 9.2.3.5. Canada Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Key Country Dynamics
      • 9.2.4.2. Target Disease Prevalence
      • 9.2.4.3. Regulatory Framework
      • 9.2.4.4. Reimbursement Framework
      • 9.2.4.5. Mexico Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Target Disease Prevalence
      • 9.3.2.3. Regulatory Framework
      • 9.3.2.4. Reimbursement Framework
      • 9.3.2.5. Uk Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Regulatory Framework
      • 9.3.3.4. Reimbursement Framework
      • 9.3.3.5. Germany Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Regulatory Framework
      • 9.3.4.4. Reimbursement Framework
      • 9.3.4.5. France Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Regulatory Framework
      • 9.3.5.4. Reimbursement Framework
      • 9.3.5.5. Italy Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Regulatory Framework
      • 9.3.6.4. Reimbursement Framework
      • 9.3.6.5. Spain Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Regulatory Framework
      • 9.3.7.4. Reimbursement Framework
      • 9.3.7.5. Denmark Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Regulatory Framework
      • 9.3.8.4. Reimbursement Framework
      • 9.3.8.5. Sweden Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Regulatory Framework
      • 9.3.9.4. Reimbursement Framework
      • 9.3.9.5. Norway Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. India Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Australia
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Regulatory Framework
      • 9.4.5.4. Reimbursement Framework
      • 9.4.5.5. Australia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Regulatory Framework
      • 9.4.6.4. Reimbursement Framework
      • 9.4.6.5. South Korea Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Regulatory Framework
      • 9.4.7.4. Reimbursement Framework
      • 9.4.7.5. Thailand Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Peptide Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. South Africa Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. UAE Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Participant Overview
  • 10.4. Financial Performance
  • 10.5. Product Bench Marking
  • 10.6. Company Market Share Analysis, 2024
  • 10.7. Company Profiles
    • 10.7.1. Eli Lilly and Company
      • 10.7.1.1. Participant's Overview
      • 10.7.1.2. Financial Performance
      • 10.7.1.3. Product Benchmarking
      • 10.7.1.4. Recent Developments/ Strategic Initiatives
    • 10.7.2. Pfizer Inc.
      • 10.7.2.1. Participant's Overview
      • 10.7.2.2. Financial Performance
      • 10.7.2.3. Product Benchmarking
      • 10.7.2.4. Recent Developments/ Strategic Initiatives
    • 10.7.3. Amgen Inc.
      • 10.7.3.1. Participant's Overview
      • 10.7.3.2. Financial Performance
      • 10.7.3.3. Product Benchmarking
      • 10.7.3.4. Recent Developments/ Strategic Initiatives
    • 10.7.4. Takeda Pharmaceutical Company Limited
      • 10.7.4.1. Participant's Overview
      • 10.7.4.2. Financial Performance
      • 10.7.4.3. Product Benchmarking
      • 10.7.4.4. Recent Developments/ Strategic Initiatives
    • 10.7.5. AstraZeneca
      • 10.7.5.1. Participant's Overview
      • 10.7.5.2. Financial Performance
      • 10.7.5.3. Product Benchmarking
      • 10.7.5.4. Recent Developments/ Strategic Initiatives
    • 10.7.6. Teva Pharmaceutical Industries Ltd.
      • 10.7.6.1. Participant's Overview
      • 10.7.6.2. Financial Performance
      • 10.7.6.3. Product Benchmarking
      • 10.7.6.4. Recent Developments/ Strategic Initiatives
    • 10.7.7. Sanofi
      • 10.7.7.1. Participant's Overview
      • 10.7.7.2. Financial Performance
      • 10.7.7.3. Product Benchmarking
      • 10.7.7.4. Recent Developments/ Strategic Initiatives
    • 10.7.8. F. Hoffmann-La Roche Ltd
      • 10.7.8.1. Participant's Overview
      • 10.7.8.2. Financial Performance
      • 10.7.8.3. Product Benchmarking
      • 10.7.8.4. Recent Developments/ Strategic Initiatives
    • 10.7.9. Novartis AG
      • 10.7.9.1. Participant's Overview
      • 10.7.9.2. Financial Performance
      • 10.7.9.3. Product Benchmarking
      • 10.7.9.4. Recent Developments/ Strategic Initiatives
    • 10.7.10. Novo Nordisk A/S
      • 10.7.10.1. Participant's Overview
      • 10.7.10.2. Financial Performance
      • 10.7.10.3. Product Benchmarking
      • 10.7.10.4. Recent Developments/ Strategic Initiatives
    • 10.7.11. GSK plc
      • 10.7.11.1. Participant's Over
      • 10.7.11.2. Financial Performance
      • 10.7.11.3. Product Benchmarking
      • 10.7.11.4. Recent Developments/ Strategic Initiatives
    • 10.7.12. Ironwood Pharmaceuticals, Inc.
      • 10.7.12.1. Participant's Overview
      • 10.7.12.2. Financial Performance
      • 10.7.12.3. Product Benchmarking
      • 10.7.12.4. Recent Developments/ Strategic Initiatives
    • 10.7.13. Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
      • 10.7.13.1. Participant's Overview
      • 10.7.13.2. Financial Performance
      • 10.7.13.3. Product Benchmarking
      • 10.7.13.4. Recent Developments/ Strategic Initiatives
    • 10.7.14. Ipsen Pharma
      • 10.7.14.1. Participant's Overview
      • 10.7.14.2. Financial Performance
      • 10.7.14.3. Product Benchmarking
      • 10.7.14.4. Recent Developments/ Strategic Initiatives

Chapter 11. Conclusion/Key Takeaways/KoL Insights

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 4 North America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 5 North America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturer, 2018 - 2030 (USD Million)
  • Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 14 Canada peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 19 Mexico peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 20 Mexico peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 21 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 22 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 24 Europe peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 Europe peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 28 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 30 UK peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 31 UK peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 32 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 33 UK peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 35 Germany peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 37 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 38 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 40 France peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 41 France peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 42 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 43 France peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 45 Spain peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Spain peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 47 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 48 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 50 Italy peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 51 Italy peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 52 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 53 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 57 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 58 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 60 Sweden peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 61 Sweden peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 62 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 63 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 65 Norway peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 66 Norway peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 67 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 68 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 76 Japan peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 77 Japan peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 78 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 79 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 81 China peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 82 China peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 83 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 84 China peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 86 India peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 87 India peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 88 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 89 India peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 91 South Korea peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 92 South Korea peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 93 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 94 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 96 Australia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 97 Australia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 98 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 99 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 100 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 101 Thailand peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 102 Thailand peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 103 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 104 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 105 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 106 Latin America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 107 Latin America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 108 Latin America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 109 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 110 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 112 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 113 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 114 Argentina peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 115 Argentina peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 116 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 117 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 119 MEA peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 120 MEA peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 121 MEA peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 122 MEA peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 123 MEA peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 124 MEA peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 125 South Africa peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 126 South Africa peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 127 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 128 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 129 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 130 UAE peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 131 UAE peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 132 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 133 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 134 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 137 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 140 Kuwait peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 141 Kuwait peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 142 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 143 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 144 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)
  • Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Million)
  • Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application segment snapshot
  • Fig. 10 Type and type of manufacturers segment snapshot
  • Fig. 11 Route of administration and synthesis technology segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Pharmaceutical market, (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 The most common cancers globally are listed in the table below
  • Fig. 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
  • Fig. 17 The figure below shows the phase of therapeutic peptides in clinical trials
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Peptide therapeutics market: Application outlook and key takeaways
  • Fig. 21 Peptide therapeutics market: Application movement analysis
  • Fig. 22 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolic disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Gastrointestinal disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Dermatological disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Renal disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Peptide therapeutics market: Type outlook and key takeaways
  • Fig. 34 Peptide therapeutics market: Type movement analysis
  • Fig. 35 Generic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Innovative market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
  • Fig. 38 Peptide therapeutics market: Type of manufacturers movement analysis
  • Fig. 39 In-house market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Outsourced market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Peptide therapeutics market: Route of administration outlook and key takeaways
  • Fig. 42 Peptide therapeutics market: Route of administration movement analysis
  • Fig. 43 Parenteral route market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Oral route market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Pulmonary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Mucosal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
  • Fig. 49 Peptide therapeutics market: Synthesis technology movement analysis
  • Fig. 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Recombinant DNA technology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Hybrid technology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Liquid-Phase Peptide Synthesis (LPPS) technology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Peptide therapeutics market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 56 Regional marketplace: Key takeaways
  • Fig. 57 Regional marketplace: Key takeaways
  • Fig. 58 North America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Target disease prevalence
  • Fig. 61 U.S. peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Target disease prevalence
  • Fig. 64 Canada peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Mexico peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Target disease prevalence
  • Fig. 68 Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 UK peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Target disease prevalence
  • Fig. 74 Germany peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Target disease prevalence
  • Fig. 77 France peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Target disease prevalence
  • Fig. 80 Spain peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Italy peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Denmark peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 Sweden peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Norway peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Rest of Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 Japan peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Target disease prevalence
  • Fig. 100 China peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Target disease prevalence
  • Fig. 103 India peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Target disease prevalence
  • Fig. 106 Australia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Thailand peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Korea peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 Brazil peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 Argentina peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Rest of Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamics
  • Fig. 122 Target disease prevalence
  • Fig. 123 South Africa peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Key country dynamics
  • Fig. 125 Target disease prevalence
  • Fig. 126 Saudi Arabia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Key country dynamics
  • Fig. 128 Target disease prevalence
  • Fig. 129 UAE peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 130 Key country dynamics
  • Fig. 131 Target disease prevalence
  • Fig. 132 Kuwait peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 133 Rest of MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)